rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-1-44-48rpcardio-1063Research ArticleORIGINAL STUDIESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯCOMPARATIVE ANALYSIS OF LOSATAN AND ENALAPRIL ANTIHYPERTENSIVE EFFICACY (ELLA TRIAL)СРАВНИТЕЛЬНЫЙ АНАЛИЗ АНТИГИПЕРТЕНЗИВНОЙ ЭФФЕКТИВНОСТИ ЛОЗАРТАНА И ЭНАЛАПРИЛА (ИССЛЕДОВАНИЕ ЭЛЛА)ЧихладзеН. М.ChihladzeN. M.СиваковаО. А.SivakovaO. A.СамедоваХ. Ф.SamedovaH. F.ЛитоноваГ. Н.LitonovaG. N.ЯроваяЕ. Б.YarovayaE. B.ЧазоваИ. Е.ChazovaI. E.Институт кардиологии им. А.Л.Мясникова Российского кардиологического научно-производственного комплекса Росмедтехнологий, МоскваРоссияInstitute of Cardiology named after A. L. Myasnikov, Russian Cardiological Research Complex of Rosmedtechnology, MoscowRussian Federation200825012016414448Copyright © Chihladze N.M., Sivakova O.A., Samedova H.F., Litonova G.N., Yarovaya E.B., Chazova I.E., 20162016Чихладзе Н.М., Сивакова О.А., Самедова Х.Ф., Литонова Г.Н., Яровая Е.Б., Чазова И.Е.Chihladze N.M., Sivakova O.A., Samedova H.F., Litonova G.N., Yarovaya E.B., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1063Aim

Aim. To compare antihypertensive efficacy of АТ1 receptors blocker (losartan) and ACE inhibitor (enalapril), including their combinations with hydrochlorothiazide.

Material and methods

Material and methods. 60 patients (30-65 y.o.) with arterial hypertension (HT) of stages 1-3 were involved in 12-week opened comparative randomized study. Patients of group-I (n=30) received losartan, patients of group-II (n=30) - enalapril. Blood pressure (BP) changes assessed on the basis of clinical measurements and ambulatory monitoring. Microalbuminuria (MAU) levels, plasma aldosterone levels and plasma renin activity were estimated.

Results

Results. Target BP levels were reached in 76,6% of patients in group-I and in 73,3% of patients in group-II. Among patients with moderate HT of stage 2 (n=50) target BP levels were reached in 96% of patients in group-I and in 72% of patients in group-II. Patients of both groups had positive changes in BP levels according to ambulatory BP monitoring. Significant reduction in MAU level and uric acid plasma concentrations were observed.

Conclusion

Conclusion. Losartan (Losap, Zentiva) and losartan combination with hydrochlorothiazide (Losap-plus, Zentiva) demonstrated antihypertensive efficacy comparable with this of enalapril as well as nephroprotective features.

Цель

Цель. Сравнить антигипертензивный эффект блокатора АТ1-ангиотензиновых рецепторов лозартана и ингибитора АПФ эналаприла (в том числе их комбинаций с гидрохлортиазидом).

Материал и методы

Материал и методы. В 12-недельное открытое сравнительное рандомизированное исследование было включено 60 больных артериальной гипертонией (АГ) разной степени тяжести в возрасте от 30 до 65 лет. Больные группы I (n=30) получали лозартан, а больные групп II (n=30) – эналаприл. Динамику артериального давления (АД) оценивали по данным клинического измерения и суточного мониторирования (СМАД). Определяли микроальбуминурию (МАУ), концентрацию альдостерона и активность ренина в плазме крови.

Результаты

Результаты. Целевой уровень АД достигнут в 76,6% случаев в группе I и в 73,3% - в группе II. В подгруппе больных с умеренной АГ 2 степени (n=50) систолическое АД нормализовалось у 96% больных в группе I и у 72% - в группе II. В обеих группах наблюдалась положительная динамика показателей СМАД. Отмечено достоверное уменьшение МАУ, а также уровня мочевой кислоты в крови.

Заключение

Заключение. Препараты лозартана (Лозап, Зентива) и лозартана в комбинации с гидрохлортиазидом (Лозап плюс, Зентива) продемонстрировали сопоставимую с эналаприлом антигипертензивную эффективность, а также нефропротективные свойства.

артериальная гипертониялозартанэналаприлмикроальбуминурияarterial hypertensionlosartanenalaprilmicroalbuminuriaReferencesVerdecchia P, Reboldi G, Angeli F et al. Angiotenzin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46(2):386-92.Verdecchia P, Reboldi G, Angeli F et al. Angiotenzin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46(2):386-92.Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25(5):951-8.Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25(5):951-8.Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995-1003.Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995-1003.Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenolol on the left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20(9): 1855-64.Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenolol on the left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20(9): 1855-64.Чихладзе Н.М., Белоусов Ю.Б., Егорова Н.А. и др. Исследование эффективности применения лозартана у больных артериальной гипертонией. Кардиоваск тер профилакт 2007;(2):5-11.Чихладзе Н.М., Белоусов Ю.Б., Егорова Н.А. и др. Исследование эффективности применения лозартана у больных артериальной гипертонией. Кардиоваск тер профилакт 2007;(2):5-11.2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105-87.2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105-87.Uribe Flores JD, Hernandes Jacome M, Guevara Donde J, Segura X. Losartan versus enalapril in the reduction of left ventricular hypertrophy secondary to systemic arterial hypertension. Arch Cardiol Mex 2004; 74(3):192-9Uribe Flores JD, Hernandes Jacome M, Guevara Donde J, Segura X. Losartan versus enalapril in the reduction of left ventricular hypertrophy secondary to systemic arterial hypertension. Arch Cardiol Mex 2004; 74(3):192-9De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16(2):133-40.De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16(2):133-40.Papademetriou V, Devereux RB, Narayan P, et al. Similar effects of isolated systolic hypertension on left ventricular geometry and function: the LIFE study. Am J Hypertens 2001; 14(8 Pt 1):768-74Papademetriou V, Devereux RB, Narayan P, et al. Similar effects of isolated systolic hypertension on left ventricular geometry and function: the LIFE study. Am J Hypertens 2001; 14(8 Pt 1):768-74Soffer BA, Wright JT, Pratt H et al. Effects of losartan on a background of hydrochlortiazide in patients with hypertension. Hypertension 1995; 26: 112-7Soffer BA, Wright JT, Pratt H et al. Effects of losartan on a background of hydrochlortiazide in patients with hypertension. Hypertension 1995; 26: 112-7Würzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19(10): 1855-60Würzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19(10): 1855-60Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimumo GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93(6): 817-21.Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimumo GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93(6): 817-21.Fang J, Alderman MH. Serum uris acid and cardiovascular mortality. The NHANES I epidemiologic followup study, 1971-1992. JAMA 2000; 283(18): 2404-10Fang J, Alderman MH. Serum uris acid and cardiovascular mortality. The NHANES I epidemiologic followup study, 1971-1992. JAMA 2000; 283(18): 2404-10Laverman GD, Andersen S, Rossing P. et al. Renoprotection with and without blood pressure reduction. Kidney Int Suppl 2005; (94):S54-9Laverman GD, Andersen S, Rossing P. et al. Renoprotection with and without blood pressure reduction. Kidney Int Suppl 2005; (94):S54-9Andersen S, Tarnow L, Rossing P et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57(2): 601-6.Andersen S, Tarnow L, Rossing P et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57(2): 601-6.

The authors declare that there are no conflicts of interest present.